Alzheimer's Disease Clinical Trials in Boston, Massachusetts

4 studies are recruiting for alzheimer's disease in Boston, Massachusetts right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Tau PET/CT Imaging in the Mismatch Prospective Cohort Study (MPC-TAU)

    To collect Tau PET/CT imaging in older adults diagnosed with Mild Cognitive Impairment (MCI) or Alzheimer's Disease (AD) in the Mismatch Prospective Cohort Study (MPC-Tau) study to determine relationship to clinical, cognitive, and other biomarker data. Findings from this study will likely provide …

    Stage
    Not phased
    Ages
    18 to 120
    Site
    Massachusetts General Hospital, Boston, Massachusetts
    Locations
    2 in total
    Run by
    University of Pennsylvania

    See if you can join NCT05658913 on ClinicalTrials.gov

  2. Dominantly Inherited Alzheimer Network (DIAN)

    The purpose of this study is to identify potential biomarkers that may predict the development of Alzheimer's disease in people who carry an Alzheimer's mutation.

    Stage
    Not phased
    Ages
    18 and older
    Site
    Brigham and Women's Hospital, Boston, Massachusetts
    Locations
    26 in total
    Run by
    Washington University School of Medicine

    See if you can join NCT00869817 on ClinicalTrials.gov

  3. A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

    The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndrome.

    Stage
    Phase 1
    Ages
    35 to 85
    Site
    Massachusetts General Hospital, Boston, Massachusetts
    Locations
    26 in total
    Run by
    AC Immune SA

    See if you can join NCT05462106 on ClinicalTrials.gov

  4. PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases

    The specific aims of the study are: Primary: To determine the presence and regional distribution of microglial activation, as assessed by Fluorine-18 (18F) labeled "Peripheral Benzodiazepine Receptor 06" (PBR06) -PET, in subjects with active Relapsing Remitting Multiple Sclerosis (RRMS), Secondary …

    Stage
    Phase 1
    Ages
    18 to 85
    Site
    Brigham MS Center, 60 Fenwood Road, Boston, Massachusetts
    Run by
    Brigham and Women's Hospital

    See if you can join NCT02649985 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.